Managing hypogammaglobulinaemia secondary to haematological malignancies in Australia and New Zealand: a clinician survey
Authors:
- Jonathan WongJWJonathan Wong
- Erica M. WoodEWErica M. Wood
- Robert WeinkoveRWRobert Weinkove
- on behalf of the Australasian Leukaemia and Lymphoma Group (ALLG) Supportive Care GroupOGon behalf of the Australasian Leukaemia and Lymphoma Group (ALLG) Supportive Care Group
- 21 August 2018
- journal article
- research article
- Published by Wiley in Internal Medicine Journal
- Vol. 49 (3) , 358-363
Abstract
Background Acquired hypogammaglobulinaemia secondary to haematological malignancies is associated with increased infection risk. Immunoglobulin (Ig) replacement reduces major infections but not mortality, and is costly. No prospective randomized trials have compared Ig replacement with prophylactic antibiotics. Aims and methods To inform trial development, we conducted an online survey of current clinical practice regarding management of secondary hypogrammaglobulinaemia among haematologists in Australia and New Zealand. Results: Seventy‐two haematologists responded; 89% of whom reported commencing Ig replacement for secondary hypogammaglobulinaemia in the setting of recurrent or severe infection. Most monitored trough IgG levels, most often 3‐monthly. Criteria for stopping Ig replacement varied. Most respondents recommended influenza and pneumococcal vaccination, while only 21% reported using antibiotic prophylaxis. Few respondents (3%) reported prescribing prophylactic antibiotics before commencing Ig replacement. Most reported an interest in recruiting patients to a clinical trial comparing Ig replacement with prophylactic antibiotics. Conclusions In comparison to limited international data, this survey finds variation in practice, which may be due to differences in local policies governing access to Ig. These findings highlight the need for research into the indications for Ig commencement and cessation, and will inform design of prospective trials of infection prevention in secondary hypogammaglobulinaemia.Keywords
Funding Information
- National Blood Authority, Australia
This publication has 18 references indexed in Scilit:
- Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinibBlood, 2015
- Antibody and Plasmablast Response to 13-Valent Pneumococcal Conjugate Vaccine in Chronic Lymphocytic Leukemia Patients – Preliminary ReportPLOS ONE, 2014
- Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent InfectionsClinical Lymphoma Myeloma and Leukemia, 2013
- Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemiaBritish Journal of Haematology, 2012
- A national clinical scenario‐based survey of clinicians' attitudes towards fresh frozen plasma transfusion for critically ill patientsTransfusion Medicine, 2010
- Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemiaClinical and Laboratory Haematology, 2008
- PROPHYLAXIS AGAINST INFECTIONS WITH INTRAVENOUS IMMUN0GLOBULINS IN MULTIPLE MYELOMABritish Journal of Haematology, 1995
- Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myelomaThe Lancet, 1994
- Cost Effectiveness of Prophylactic Intravenous Immune Globulin in Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 1991
- Intravenous Immunoglobulin for the Prevention of Infection in Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 1988